melanoma

Exelixis and Genentech hammer out new deal terms
Exelixis and Genentech hammer out new deal terms
BioPharma Dive
Exelixis
Genentech
Cotellic
melanoma
Flag link:
Bristol Myers Vies to Be King of Immuno-Boosting Cancer Drugs with New Trial Update
Bristol Myers Vies to Be King of Immuno-Boosting Cancer Drugs with New Trial Update
TheStreet.com
Bristol-Myers Squibb
Opdivo
melanoma
Flag link:
Personalized cancer vaccines vanquish melanoma in small but encouraging study
Personalized cancer vaccines vanquish melanoma in small but encouraging study
Stat
personalized medicine
cancer
vaccines
melanoma
Keytruda
Merck
Neon Therapeutics
Flag link:
Bristol-Myers’ tarnished checkpoint star Opdivo beats out Yervoy in surprise PhIII
Bristol-Myers’ tarnished checkpoint star Opdivo beats out Yervoy in surprise PhIII
Endpoints
Bristol-Myers Squibb
Opdivo
Yervoy
melanoma
Flag link:
Checkmate Pharma Clinches $27M for More Studies in Skin Cancer
Checkmate Pharma Clinches $27M for More Studies in Skin Cancer
Xconomy
Checkmate Pharmaceuticals
melanoma
Keytruda
Merck
Flag link:
How Far Into the Drug Pipeline Should the FTC Reach?
How Far Into the Drug Pipeline Should the FTC Reach?
TheStreet.com
FTC
GSK
Novartis
BRAF inhibitor
MEK inhibitor
melanoma
Array Biopharma
M&A
Flag link:
Bristol-Myers Squibb says cancer drug combination 'significantly' improved survival in late-stage melanoma trial
Bristol-Myers Squibb says cancer drug combination 'significantly' improved survival in late-stage melanoma trial
Marketwatch
Bristol-Myers Squibb
Opdivo
Yervoy
melanoma
Flag link:
Why NewLink Genetics Shares Fell 10.3% Today
Why NewLink Genetics Shares Fell 10.3% Today
Motley Fool
NewLink Genetics
indoximod
melanoma
Flag link:
For Bristol-Myers, A Victory And A Mystery
For Bristol-Myers, A Victory And A Mystery
Forbes
Bristol-Myers Squibb
Opdivo
melanoma
Flag link:
Merck, Incyte Expand Cancer Collaboration
Merck, Incyte Expand Cancer Collaboration
Barron's
Merck
Incyte
epacadostat
Keytruda
melanoma
Flag link:
Array walks back its FDA pitch on binimetinib, derailing plans for commercial launch
Array walks back its FDA pitch on binimetinib, derailing plans for commercial launch
Endpoints
Array Biopharma
FDA
binimetinib
NRAS-positive melanoma
melanoma
Flag link:
Roche flags early success for Tecentriq combos, hustles into PhIIIs
Roche flags early success for Tecentriq combos, hustles into PhIIIs
Endpoints
Tecentriq
Roche
clinical trials
melanoma
Flag link:
New Bristol-Myers Squibb Research on Opdivo (nivolumab) Monotherapy and in Combination With Yervoy (ipilimumab) at SMR 2016 Congress Reinforces Immuno-Oncology Leadership and Scientific Expertise in Melanoma
New Bristol-Myers Squibb Research on Opdivo (nivolumab) Monotherapy and in Combination With Yervoy (ipilimumab) at SMR 2016 Congress Reinforces Immuno-Oncology Leadership and Scientific Expertise in Melanoma
Yahoo
Bristol-Myers Squibb
Opdivo
Yervoy
melanoma
Flag link:
These 3 Little Biotechs Just Scored Big
These 3 Little Biotechs Just Scored Big
Motley Fool
biotech
Celldex Therapeutics
melanoma
glemba
Exelixis
Cabometyx
renal cell carcinoma
Tesaro
ovarian cancer
niraparib
Flag link:
3 Cancer Drugs That Could Get an FDA OK Next Year
3 Cancer Drugs That Could Get an FDA OK Next Year
Motley Fool
FDA
rucaparib
Clovis Oncology
ovarian cancer
binimetinib
Array Biopharma
melanoma
brigatinib
Ariad Pharmaceuticals
non-small cell lung cancer
Flag link:
Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress
Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress
Yahoo
Merck
Keytruda
melanoma
Flag link:
Opdivo: The Oncology Blockbuster for Bristol-Myers Squibb
Opdivo: The Oncology Blockbuster for Bristol-Myers Squibb
Market Realist
Opdivo
Bristol-Myers Squibb
melanoma
lung cancer
Flag link:
Celldex Rose on Phase 2 Melanoma Data
Celldex Rose on Phase 2 Melanoma Data
Market Realist
Celldex
melanoma
CDX‑1401
CDX-301
Flag link:
New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting
New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting
Yahoo
Keytruda
Merck
ASCO 2016
melanoma
Flag link:
Merck, Bristol drugs show longer survival for deadly cancers
Merck, Bristol drugs show longer survival for deadly cancers
Yahoo/Reuters
Merck
Bristol-Myers Squibb
cancer immunotherapy
lung cancer
melanoma
Opdivo
Keytruda
ASCO 2016
Flag link: